Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13598351 | 0.83 | PPARD (0.41) | PPARDPPARA | |
| SCHEMBL3848326 | 0.83 | PPARD (0.41) | PPARDPPARA | |
| SCHEMBL3847852 | 0.83 | PPARD (0.41) | PPARDPPARA | |
| SCHEMBL3975314 | 0.79 | PPARD (0.39) | PPARDPPARA | |
| SCHEMBL3974229 | 0.77 | CA1 (0.51) | PPARDPPARA | |
| SCHEMBL3848313 | 0.75 | HTR1D (0.40) | PPARDPPARA | |
| SCHEMBL3973535 | 0.74 | CA1 (0.42) | PPARDPPARA | |
| SCHEMBL6446082 | 0.72 | PPARD (0.35) | PPARDPPARA | |
| SCHEMBL3973524 | 0.72 | MTNR1A (0.51) | — | |
| SCHEMBL13598332 | 0.70 | PPARD (0.41) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554240-B1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-06 | — | — | EP | disclosed |
| US-7351857-B2 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-01 | — | — | US | disclosed |
| US-20060247314-A1 | Substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | US | disclosed |
| US-20060094786-A1 | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-04 | — | — | US | disclosed |
| US-20060074130-A1 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-06 | — | — | US | disclosed |
| EP-1569897-A1 | SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-07 | — | — | EP | disclosed |
| EP-1554240-A1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-20 | — | — | EP | disclosed |
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-02 | — | — | US | disclosed |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-26 | — | — | US | disclosed |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-19 | — | — | US | disclosed |
| WO-2004037779-A1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037778-A1 | SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094786-A1 | Treating syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | PPARD 3/4885PPARA 2/4885 |
| US-20060074130-A1 | Methods of using substituted tetralins and indanes | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | PPARD 3/4885PPARA 2/4885 |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | PPARD 3/4885PPARA 2/4885 |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
| US-20060247314-A1 | Substituted tetralins and indanes | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.